header logo image


Page 23«..1020..22232425..3040..»

Archive for March, 2020

US visa policy violates the human rights of transplant candidates and the terminally ill | TheHill – The Hill

Sunday, March 15th, 2020

Can you imagine needing a life-saving transplant and then having a family member, who is an exact donor match, denied entry into the U.S. for a medical procedure that could save your life? Or being denied your dying wish to see your foreign parent, sibling or child because they could not gain permission to enter the U.S.? For many patients, this is a harsh reality and a violation of their basic human rights.

For three years I was a lawyer with New York Legal Assistance Group (NYLAG) LegalHealth division and provided free civil legal services to New York City hospital patients with low income. Transplant teams sought my assistance when plans for a patients transplant were stalled after a family member who was an exact donor match had been denied a visitor visa to travel to the U.S. Palliative care teams sought my assistance for terminally ill patients who wished to see a family member before they died, but the loved one had been denied a visitor visa.

Whether a patients family member is able to secure a visitor visa is entirely at the discretion of the U.S. Department of State consular officer who is adjudicating the visa application. If the officer is not persuaded that the family member will return home after their temporary stay in the U.S., the officer will deny the visitor visa under Section 214(b) of the U.S. Immigration and Nationality Act. This law creates an automatic presumption that anyone who applies for a visitor visa actually intends to remain in the U.S. permanently. This presumption of immigrant intent can only be overcome if an applicant demonstrates sufficiently strong familial, social, professional and economic ties to a country other than the U.S.

Citizens of 38 (mostly European) Visa Waiver Program countries are not required to obtain visas for short visits to the U.S. In contrast, citizens of African countries and most Latin American and Asian countries are excluded from the Visa Waiver Program. As a result, patients of African, Latin American and Asian-descent have a much harder time bringing their family members to the U.S. for transplants and end-of-life companionship.

Most of my clients were experiencing poverty. Their family members often could not show proof of financial ties needed to overcome the presumption of immigrant intent. In such cases, I helped the seriously ill client request assistance from their elected representatives, who sometimes then engaged in quiet diplomacy with the State Department on behalf of the constituent. But even with the help of lawyers and elected officials, many visas are denied, and denials cannot be appealed.

The discretionary standard for evaluating immigrant intent is unjust and violates fundamental principles of human rights. The International Covenant on Civil and Political Rights (ICCPR), which the U.S. has adopted, states that no individual should be arbitrarily deprived of his or her life. It also recognizes that family is the fundamental unit of society and is entitled to protection by the government. These basic principles are violated when a patient dies waiting for a donor match to be allowed into the U.S., or is denied the comfort of being with close family before death.

The story of my client Jocelyn (whose name has been changed to protect her identity) illustrates the current systems flaws. Jocelyn was a naturalized U.S. citizen who became ill with an aggressive blood cancer in her early forties. Her sister in Guyana was determined to be an exact donor match for a stem cell transplant. As the caregiver for their aging mother, Jocelyns sister had no income and was unable to obtain a visitor visa. With no other viable donor source available, Jocelyn died awaiting a transplant.

A simple reform to current visa policy would prevent tragedies like Jocelyns from occurring. The discretionary standard for granting or denying a visitor visa should be dispensed with for two categories of visitor visa applicants:Those who are certified by a physician to be an exact donor match for a U.S. citizen or lawful immigrant, and the immediate family members of a U.S. citizen or lawful immigrant who has a terminal illness. A new emergency visa category should be created for these visa applicants, with its own set of conditions to minimize the risk of visitor overstays.

Bipartisan support for legislative and policy reform potentially exists. Just last fall, after congressional hearings and significant opposition, the Trump Administration reversed its decision to end medical deferred action, which allows undocumented immigrants suffering from life-threatening conditions to request to remain in the U.S. with authorization temporarily to obtain medical treatment that is unavailable in their home countries, without which they will likely die. Medical and legal communities had challenged the decision, arguing that no one should be denied life-saving medical treatment just because of their immigration status. The same commonsense notion applies here. Transplant candidates should not die because of the vagaries of consular officers, and terminally-ill patients should be able to die with dignity, surrounded by their loved ones, regardless of their familys origin. Reforming U.S. visitor visa policy by creating an emergency visa category for donor matches and close family of terminally ill patients would ensure that the fundamental principles of human rights and basic decency are respected.

Christina T.Holderis public interest counsel at Lowenstein Sandler LLP. She previously worked as a senior staff attorney at New York Legal Assistance Group.

View post:
US visa policy violates the human rights of transplant candidates and the terminally ill | TheHill - The Hill

Read More...

Week In Review: Nanjing Legend Files To Stage IPO In The U.S. – Seeking Alpha

Sunday, March 15th, 2020

Deals and Financings

Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (OTC:GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson & Johnson (NYSE:JNJ) partnered the treatment in a deal that paid Legend $350 million upfront, plus unspecified milestones and royalties. The CAR-T candidate, JNJ-4528, is now in Phase II trials in the US.

Harbour BioMed (HBM) raised $75 million in a Series B+ round to advance its clinical-stage compounds and portfolio of next-gen biotherapies for cancer and immunological diseases. The company builds its portfolio by in-licensings and via its proprietary Harbour Mice program. Harbour develops drugs for China and US markets, while it has entered partnerships to discover candidates for China companies Innovent (OTCPK:IVBIY) and BeiGene (NASDAQ:BGNE), along with other prominent global biopharmas. The company previously completed an $85 million Series B financing in August 2018. HBM is headquartered in Cambridge, MA, and it conducts R&D in Suzhou and Shanghai.

GenFleet Therapeutics (Shanghai) closed a $57 million Series B financing, co-led by CDH Investments and Shenzhen Capital Group. Founded in 2017, GenFleet is developing novel large and small therapeutic molecules for oncology and immunology targets. The company says its projects are potential first-in-class therapeutics with technical advantages and large markets. It will use the capital for ex-China development and clinical trials of its existing pipelines, plus expanding its immunology platform, working on new projects and building an industrial base.

Arctic Vision of Shanghai in-licensed greater China rights to Xipere, a treatment for macular edema associated with uveitis, from Clearside Bio (NASDAQ:CLSD) in a $35.5 million agreement. Founded last year, Arctic in-licenses breakthrough ophthalmology products for China. Xipere is its first deal. Arctic plans to acquire China rights to 3-5 products and then expand to a combination of global rights and internal discovery for additional drugs. Clearside, which is located in Alpharetta, Georgia, said Xipere is a proprietary suspension of the corticosteroid triamcinolone acetonide.

Exuma Biotech (formerly F1 Oncology), a Florida-Shanghai company developing CAR-T products for solid tumors, closed a $19 million Series B round. The financing included investments from MSD Partners and F1 BioVentures, plus conversion of notes held by individual investors. Exuma's Logic Gated CAR-T products become activated only when the target antigen and the tumor microenvironment are both present, reducing off-tumor side effects. The company has started clinical trials of two candidates. Exuma's Shanghai subsidiary oversees the company's development, manufacturing, and commercial units in Shanghai and Shenzhen.

OBiO Technology (Shanghai) completed a B+ Round of more than $15 million for its viral-based gene therapy CRO services and genetic drug CDMO/CMO services. Founded in 2013, OBiO collaborated with GE Healthcare (NYSE:GE) to establish the first domestic GMP viral production workshop in China and supply CRO/CDMO/CMO services for viral drugs. At the same time, OBiO is incubating gene therapy drugs for cancer therapy with three ADC candidates for oncotherapy that have proprietary IP. The B+ Round investors included GP Capital, Sinowisdom and Efung Capital.

Shanghai OPM Biosciences raised $14 million from China Life Medical Fund to support its CDMO service platform. The company offers serum-free media for cell cultures based on animal cells, as well as a full-range of cell culture development services. It customizes high-quality personalized animal cell culture media to optimize the cell culture process and reduce production costs. OPM has developed a variety of chemically defined CHO/HEK293 cell culture media and nutritional products. The company claims its media improve cell growth and expression.

China Immunotech Biotech of Beijing completed a $6.5 million Series A financing, led by Jianxin Capital with Grower Venture Capital and Huacheng Group participating. Founded in March 2018, China Immunotech is developing TCR-T and CAR-T products that target hematological tumors, solid tumors and virus-related diseases. It has two unique technology platforms, STAR-T and TCR-T. The STAR-T platform uses a proprietary structure of antigen receptor complexes. The company believes the platform provides multi-targeted molecules with better efficacy, fewer side effects and easier development than traditional CAR-T products.

Chengdu's HitGen has signed a licensing agreement to develop a novel class of drugs for Kaken, a Japanese (TK: 4521) specialty pharma. HitGen has already used its large library of small molecule and macrocyclic compounds to identify potential candidates. Few details were released, but Kaken is known to be concentrating its R&D on inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infections. One year ago, the two companies formed a similar collaboration, presumably for other targets. HitGen will receive an upfront payment and be eligible to receive preclinical and clinical milestones.

Suzhou Ascentage Pharma (HK: 6855) announced approvals for three clinical studies of APG-2575, a novel Bcl-2 inhibitor, two in the US and one in China. APG-2575 is an oral drug designed to treat several hematologic malignancies by blocking Bcl-2 to restore the normal apoptosis process in cancer cells. According to Ascentage, the candidate is the first China-made Bcl-2 inhibitor to start clinical trials. In its Phase I clinical studies, APG-2575 did not exhibit any dose-limiting toxicity or tumor lysis syndrome (which is commonly associated with other Bcl-2 inhibitors).

Denovo Biopharma, a San Diego-Beijing precision medicine company, has discovered a novel genetic biomarker for depression that it intends to use with DB104, a triple dopamine, serotonin and norepinephrine reuptake inhibitor. The company made the discovery using its proprietary biomarker discovery platform. Denovo licensed DB104 from Albany Molecular Research. Bristol-Myers Squibb (NYSE:BMY) returned the candidate to Albany after two Phase IIb clinical trials in treatment-resistant depression. The biomarker is one of four DeNovo biomarkers aimed at psychiatric use.

I-Mab (NASDAQ:IMAB), a Shanghai clinical-stage biopharma, has started to develop TJM2 (TJ003234) to treat cytokine release syndrome in severe cases of COVID-19. TJM2 is an I-Mab-discovered neutralizing antibody that binds human granulocyte-macrophage colony stimulating factor (GM-CSF), an important cytokine that plays a critical role in acute and chronic inflammation. By binding GM-CSF, TJM2 prevents downstream signaling and target cell activation, inhibiting other inflammatory responses. I-Mab intends to start clinical trials in the US and expand to countries especially hard-hit by COVID-19.

Mesoblast (NSDQ: MESO; ASX: MSB), an Australia-based regenerative medicine company, announced plans to start trials of remestemcel-L, its allogeneic mesenchymal stem cell (MSC) product candidate, in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19. The trial will be conducted in the US, Australia, China and Europe. ARDS is the principal cause of death in COVID-19 patients. In a small China trial, allogeneic MSCs cured or significantly improved all seven patients with severe COVID-19 pneumonia.

Ascletis (HK: 1672), a Hangzhou biopharma, reported that an initial group of 11 COVID-19 patients all recovered after being treated with a combination Ganovo and Ritonavir therapy. Ascletis's Ganovo, the first approved direct-acting anti-viral agent developed by a China company, was launched in 2018 to treat hepatitis C. Ritonavir is a generic anti-retroviral that is used in AIDS/HIV combination therapies. The small clinical trial was led by Dr. Hongyi Chen, the director of the Ninth Hospital of Nanchang.

Disclosure: None

Original Post

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.

Read the original here:
Week In Review: Nanjing Legend Files To Stage IPO In The U.S. - Seeking Alpha

Read More...

Why people with diabetes, like Tom Hanks, may be at increased risk of coronavirus – USA TODAY

Sunday, March 15th, 2020

Tom Hanks and his wife Rita Wilson have tested positive for coronavirus while working in Australia. USA TODAY

As the new coronavirus spreads and sickens more people in the USA, people with preexisting health conditions areat particular risk, public health officials say.

Actor Tom Hanks, who revealed that he was living with Type 2 diabetes in 2013, confirmed Wednesday that he and his wife tested positive for the coronavirus that causes COVID-19.

People with diabetes are among those at increased risk for complications from COVID-19, the Centers for Disease Control and Prevention says.

That's becausefluctuations in blood glucose levelsand possible diabetes complications can make it harder to treat a viral infection, the International Diabetes Federationsays.

The latest on coronavirus: EU rips travel ban; US stocks struggle; NBA suspends season; US death toll at 38

Though doctors are still learning what exactly puts someone at higher risk for developing a severe illness with COVID-19, early information indicates older patients and those with chronic medical conditions may be at higher risk.

According to early data frommore than 44,000 confirmed casesin China as of Feb 11, deaths among patients who had diabetes were at 7%, compared with 0.9% for those without an underlying condition, the CDC says.

According to theInternational Diabetes Federation, there may be two reasons for the complications that can arise.

"Firstly, the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period," the group wrote in its "Diabetes Voice" publication. "Secondly, the virus may thrive in an environment of elevated blood glucose."

Q&A: You asked us tons of questions about the coronavirus. We answered them.

"Diabetes affects healing in general," said Dr.Susan Spratt, an endocrinologist at Duke University. Patients who have diabetes can have an increased risk of taking more time to heal and get a secondary infection, Spratt said.

People with diabetes can't make enough or can't as effectively usethe insulin in their bodies, according to the CDC. Insulin helps people use sugar in their bloodstreams for energy. As the food we eat breaks down into sugar, or glucose, it is released into our blood, and our pancreas releases insulin to facilitate the process.

"When there isnt enough insulin or cells stop responding to insulin, too much blood sugar stays in your bloodstream. Over time, that can cause serious health problems, such as heart disease, vision lossand kidney disease," the CDC says.

When a patient's diabetes is uncontrolled, meaning blood sugar levels are not in a recommended range, this can especially contribute to heart or kidney problems, said Dr. Maria Pea, director of endocrine services at Mount Sinai Doctors Forest Hills in New York.

Having both problems with their heart or kidney and diabetes could worsenthe prognosis for patients with COVID-19, she said.

Another potential issue for patients with diabetes amid the COVID-19 outbreak is inflammation, saidPea.

Increased blood sugar can increase inflammation, as can viral infections,Pea said. With bothincreasinginflammation, this can increase the likelihood of a more severe complication, she added.

People with diabetes, even those with the condition well managed, are at a higher risk of complications from the flu as well, the CDC says.

Patients with Type 1 diabetes, caused when a person's immune system attacks the cells in their pancreas that create insulin, are at an increased risk fordiabetic ketoacidosis. "This can make fluid and electrolyte management even trickier when trying to manage sepsis," Spratt said.

According to research published Wednesdayin the medical journal The Lancet, sepsis and septic shock are among the severe complications observed in some COVID-19 cases.

The CDC recommends people with preexisting conditions take everyday precautions to protect themselves from COVID-19. This includes avoiding contact with sick people, washing their hands regularly and not touching their face, among other measures.

Those who have a condition such as diabetes should make sure they're in contact with their doctor if they need extra medication or supplies, such astest strips or insulin.

The American Diabetes Associationrecommends gatheringsimple carbs such asregular soda, honey, jam,Jell-O, hard candies or popsicles.

"If you have diabetes and you have symptoms such as cough, high temperature and feeling short of breath, you need to monitor your blood sugar closely," Dan Howarth, head of care at Diabetes UK, said in a statement.

Follow USA TODAY's Ryan Miller on Twitter @RyanW_Miller

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/03/12/tom-hanks-coronavirus-actor-has-covid-19-diabetes-heres-risk/5030111002/

Original post:
Why people with diabetes, like Tom Hanks, may be at increased risk of coronavirus - USA TODAY

Read More...

Defeating Diabetes: What you don’t know can kill you. Take the test – KTBS

Sunday, March 15th, 2020

Bossier, La. - More than 7-million American adults have diabetes and don't know it. That's about one in four people. And with diabetes, what you don't know can kill you.

There is absolutely no way to tell who in this crowd has diabetes, "You don't just go to bed one day and wake up the next and you're diabetic," says Endocrinologist, Laura E. Kimball-Ravari, M.D.

There are symptoms that go unnoticed leaving one-third of diabetes cases undiagnosed, "Changes and differences in your body from having high blood sugars can start early on," says Ravari. She adds, the sooner a person discovers they're diabetic the better.

"Diabetes is the leading cause of blindness in adults, the leading cause of kidney failure requiring hemodialysis, the leading cause of lower limb amputation," says Ravari.

Tiffany McCallister was just a toddler when her mother suspected something might be wrong, "She took me to the doctor and they said there was nothing wrong."

At that time, blood glucose tests weren't as accurate. Her mother got a second opinion, "And immediately smelled my breath and said she's a diabetic."

Tiffany has Type1. Diabetes typically considered the type that affects children, "But, they can also be diagnosed when they're much older, even 30's and 40's. But, they're usually a more slender build and are normally more fit," adds Ravari.

Still the first step is diagnosis which means knowing the symptoms. "You do have to look for the symptoms of diabetes, and some of the symptoms are being very hungry, being very tired, and maybe having some blurry vision," says Ravari.

Frequent urination is also a symptom. A person might also have cuts that don't properly heal.

Diagnosed as a toddler, to Tiffany managing diabetes is a way of life. Whether you're a Type 1 or Type 2 diabetic, going undiagnosed could be deadly, "I've had it a long time. And the best thing, take care of yourself and don't limit yourself."

If you are experiencing any of the symptoms - make an appointment with a doctor. The longer diabetes goes undiagnosed, the more damage it can cause. Prevalence of the disease is expected to increase by 54-percent in the next 10 years.

More:
Defeating Diabetes: What you don't know can kill you. Take the test - KTBS

Read More...

Artificial Intelligence in Diabetes Management Industry to Generate Revenues of Over $1.26 Billion by 2024 – Infinium Global Research – Benzinga

Sunday, March 15th, 2020

PUNE, India, March 13, 2020 /PRNewswire/ -- Infinium Global Research has recently published a global report on "Artificial Intelligence in Diabetes Management Market(Device - Insulin Delivery Devices, Diagnostic Devices, and Glucose Monitoring Devices): Global Industry Analysis, Trends, Size, Share and Forecasts to 2024", the reported study estimated the market for artificial intelligence in diabetes management will reach up to USD 1264.7 million by 2024, with a compound annual growth rate of 47.5%, in the forecast period (2018-2024).

Digitization has made big data technologies more relevant in the healthcare environment. The propagation of smart devices has enhanced the transition to digitized healthcare. The smart apps have made self-management of diabetes by the patients affordable. Sensors are proficient in transmitting data to smart devices and diabetics can monitor their blood glucose levels on these devices. Pharmacogenetics and machine learning will help systems embedded with artificial intelligence to manage diabetes better than humans in the near future. Artificial intelligence algorithms bring about advanced glucose prediction methods that help in tackling diabetes effectively.

Furthermore, artificial intelligence is leveraging the avalanche of healthcare data and is improving patient outcomes for diabetes patients. Machine learning algorithms allow better diagnosis and monitoring resulting in enhanced patient-centric treatment. It is predicted that diabetes will extensively be managed by smart machines and artificial intelligence algorithms over the forecast period.

Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/3241

Increasing Prevalence of Diabetes Globally

Diabetes is a medical condition wherein the inability of the pancreas to produce insulin causes augmented glucose levels in the body. Presently, the major part of the world is suffering from type 2 diabetes to a greater extent. Furthermore, genetics and an unhealthy lifestyle are considered as major causes of diabetes mellitus. Diabetics face various daily challenges such as dietary restrictions and regular administering of insulin. The anytime-anywhere nature of digital technology allows patients to address their health problems by connecting with the healthcare team and sharing data. This is creating a digital ecosystem of data driven tools that can associate patients and their care team for better management of diabetes.

Moreover, the government programs are running across the world in order to control diabetes. Numerous software companies come with an idea of several applications in diabetes management which would help in controlling and managing diabetes. Growing use of mobile phones permits these companies to design apps which directly or indirectly help to manage the diabetes mellitus.

Increasing Penetration of Connected Devices and other Wireless Technology Will Spur Revenue Growth

The global artificial intelligence in diabetes management market is anticipated to witness the exceptional growth during the estimated period. The growth is primarily associated with the increasing prevalence of the geriatric population across the globe. In addition, the rising prevalence of metabolic disorders together with increasing adoption of a torpid or sedentary lifestyle also contributes to boosting the growth of artificial intelligence in the diabetes management market.

However, few factors such as government regulation, a dearth of awareness, and high cost are the major restraints limiting the growth of artificial intelligence in the diabetes management market. Nevertheless, various research and technological developments are considered as better opportunities that help in bringing new growth paths for artificial intelligence in the diabetes management market over the forecast period.

Novel Solutions Offered by Several Companies and Digital Health Start-Ups Assist in Revenue Growth

The key players are investing in integrated Artificial Intelligence technology with other technologies such as the Internet of Things (IoT), Natural Language Processing (NLP), and Machine Learning (ML). Launch of the technologically advanced and economical system by key players in the market are projected to propel the growth of the market during the forecast period. Various companies are also providing a wide range of devices and software portfolio to offer advanced solutions to their customers.

Furthermore, mergers & acquisitions, strategic partnerships, collaboration, and agreement are some of the major strategies adopted by industry vendors to sustain competition in the market. For instance, in June 2019, Companion Medical, a leader in the development of advanced insulin delivery technology to improve diabetes care, and Glooko, a leader in diabetes data visualization and management, have declared an incorporated data partnership agreement that will permit insulin data from users of the InPen Smart Insulin Injection Pen to be integrated into the Glooko Enterprise diabetes data management system and Glooko Mobile App. This amalgamation will assist users to automatically incorporate their insulin data with the Glooko diabetes data management system for medical evaluation by their healthcare professionals.

Evolving Healthcare Infrastructure in Developing Nations Enables Market Growth in Asia Pacific

North America region is estimated to remain its dominance in artificial intelligence in the diabetes management market during the prediction period due to growing innovation in artificial intelligence-based solutions. Furthermore, North America is in the next phase of digitization of concepts like the Internet of Things, big data, robotics, and machine learning. Consequently, these digital technologies are expected to drive the regional market over the projection period. The Asia Pacific region is anticipated to witness an enormous growth in the near future owing to new product launches and a huge diabetes population base.

In addition, the Asia Pacific region is also witnessing numerous product launches. For instance, in May 2019, Roche Diabetes Care India introduced its Integrated Diabetes Management Solution (IDMS) program in India along with the introduction of the Accu-Chek Instant blood glucose monitoring (BGM) system and the My Sugar app. Moreover, the government of China is promoting the development of artificial intelligence in the healthcare sector and offering funds for smart healthcare facilities.

Need Assistance? Send an Enquiry@ https://www.infiniumglobalresearch.com/reports/enquiry/3241

Global Artificial Intelligence in Diabetes Management Industry Coverage

Chapter - 1 Preface

Chapter - 2 Executive Summary

Chapter - 3 Global Artificial Intelligence in Diabetes Management Market Overview

Chapter - 4 Artificial Intelligence in Diabetes Management Market Macro Indicator Analysis

Chapter - 5 Global Artificial Intelligence in Diabetes Management Market by Device

Chapter - 6 Global Artificial Intelligence in Diabetes Management Market by Region 2018-2024

Chapter - 7 Company Profiles and Competitive Landscape

Browsein-depth TOC on "Artificial Intelligence in Diabetes Management Market"

About Us

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide the knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

Contact:

Mr. Shrikant AthavaleInfinium Global ResearchOffice No. 103 and 104,Suratwala Mark Plazzo,Hinjawadi, Pune,Maharashtra,Pin- 411057.USA: 1-888-500-3114Email:info@infiniumglobalresearch.com Research Insight:https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-artificial-intelligence-in-diabetes-management-marketVisit Our Web Site:https://www.infiniumglobalresearch.com

View original content:http://www.prnewswire.com/news-releases/artificial-intelligence-in-diabetes-management-industry-to-generate-revenues-of-over-1-26-billion-by-2024---infinium-global-research-301022814.html

SOURCE Infinium Global Research

Read this article:
Artificial Intelligence in Diabetes Management Industry to Generate Revenues of Over $1.26 Billion by 2024 - Infinium Global Research - Benzinga

Read More...

Type 2 diabetes and coronavirus: How to lower risk of catching virus if you have diabetes – Express

Sunday, March 15th, 2020

Type 2 diabetes is not a major concern in and of itself, but if left untreated, the condition can lead to a number of deadly complications, such as heart disease. This is because your blood sugar levels are more prone to fluctuating if you have diabetes, and this mechanism damages blood vessels and impairs other vital bodily functions. There is now a threat that has been added to the list of potential complications: COVID-19.

COVID-19 is a new strain of virus that belongs to the coronavirus group, a family of respiratory infections.

The virus, which first broke out in the Wuhan province in China in December, has so far caused 124,933 cases worldwide and lead to 4,585 fatalities.

Scientists gathering data on the pathogen have revealed that infected people with diabetes are more prone to developing a serious illness.

It is believed that diabetes can weaken your immune systems defences, leaving you more susceptible to illness.

READ MORE:Type 2 diabetes: How much sleep you need each night to keep blood sugar levels in check

According to official reports, older people, those with a compromised immune system and those with high blood pressure or heart problems, are at an increased risk of developing a serious illness.

People with diabetes should also heed the advice issued to the general public on how to reduce the risk of catching and spreading the virus.

Thoroughly washing your hands with soap and water for at least 20 seconds is the most important measure.

Take notice of areas you might miss including the back of your hands, between your fingers and around the nails, advises Diabetes.co.uk.

Originally posted here:
Type 2 diabetes and coronavirus: How to lower risk of catching virus if you have diabetes - Express

Read More...

Prevent the silent epidemic of kidney disease – The Baxter Bulletin

Sunday, March 15th, 2020

Jim Miller, The Savvy Senior Published 3:47 p.m. CT March 15, 2020

Jim Miller(Photo: File)

Dear Savvy Senior,

Do kidney problems run in families? My mother died from kidney failure 10 years ago at age 74 but didnt know she had a kidney problem until it was too late.

Just Turned 60

Dear 60,

Anyone who has a family history of kidney disease, or who has high blood pressure or diabetes is at increased risk and needs to have their kidneys tested.

According to the Center for Disease Control and Prevention, around 37 million U.S adults have chronic kidney disease (when the kidneys cant properly do their job of cleaning toxins and wastes from the blood), and millions more are at risk of developing it, yet most people dont realize it. Thats because kidney disease develops very slowly over many years before any symptoms arise. But left untreated, the disease can eventually require people to spend hours hooked up to a dialysis machine or get a kidney transplant. Even mild kidney problems can double a persons risk of heart attack and stroke, as well as cause anemia and bone disease.

The reason kidney disease has become so widespread today is because of the rise of obesity, type-2 diabetes and high blood pressure which all strain the kidneys.

Another factor is the increasing number of people who take multiple medications, which can overtax the organs. People over age 60 are especially vulnerable both because they tend to take more drugs, and because kidney function normally declines somewhat with age.

Because kidney disease has no early symptoms, the only way to catch it before it advances is to have a simple blood and urine test by your doctor. So, anyone that has diabetes, high blood pressure or heart disease, a family history of kidney disease, or is age 60 or older needs to get tested. African, Hispanic, Asian and Indian Americans along with Pacific Islanders are also at increased risk.

If youre diagnosed with kidney disease you need to know that theres no cure, but there are steps you can take to help contain the damage, including:

Control your blood pressure: If you have high blood pressure, get it under 130/80. If you need medication to do it, ACE inhibitors and ARBs are good choices because of their proven ability to protect the kidneys.

Control your diabetes: If you have diabetes, keep your blood sugar as close to normal as possible.

Change your diet: This usually means reducing the amount of protein and phosphorus you eat and cutting back on sodium and possibly potassium. Your doctor can help you determine an appropriate eating plan, or you may want to talk to a dietitian.

Watch your meds: Dozens of commonly used drugs can damage the kidneys, especially when taken in high doses over long periods most notably NSAIDs like ibuprofen and naproxen. Herbal supplements can also be very dangerous. Talk to your doctor about all the prescription, over-the-counter and herbal products you take to identify potential problems and find alternatives.

Exercise and lose weight: If youre overweight and inactive, start an aerobic fitness routine (walk, swim, cycle, etc.) that gets your heart pumping. This will help lower blood pressure, control diabetes and help you lose excess weight all of which will help your kidneys.

Quit smoking: If you smoke, quit. Heart disease becomes a much greater risk to the kidneys if your smoke. Smoking also doubles the rate of progression to end-stage renal failure.

Limit alcohol intake: Drinking too much alcohol can worsen kidney disease too, so talk to your doctor to see if its safe for you to drink, and if so, limit yourself to no more than one drink per day.

Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of The Savvy Senior book.

Read or Share this story: https://www.baxterbulletin.com/story/news/local/2020/03/15/prevent-silent-epidemic-kidney-disease/5054616002/

Continue reading here:
Prevent the silent epidemic of kidney disease - The Baxter Bulletin

Read More...

Wear The Gown: Rolling back diabetes with diet and exercise – KENS5.com

Sunday, March 15th, 2020

SAN ANTONIO For many who develop type-2 diabetes, they become reliant on medicationand, in many cases, more than one type. But it is possible to roll back diabetes and get off the medications with diet and exercise.

"It was eight-point-something and now we are down to 5.7, which is borderline diabetic. Anything under six is where I want to stay," said Armida Oliver, a diabetes patient for the past 10 years, while discussing her A1C number. "That was about two or three years ago. I'm down to just one medication and my numbers have been great."

At one point she was taking three medications: Metformin, Januvia, and Invokana. But thanks to diet and exercise, she managed to drop two of them, along with 55 pounds.

"I join my sisters for senior water aerobics every morning. We try Monday through Friday, but we are happy if we go four times a week," Oliver said.

Some of the benefits of exercise for diabetes includes lowered blood sugar levels, improved insulin sensitivity, reduced body fat, a lowered risk of heart disease and an enhanced quality of life.

RELATED: Wear The Gown: The dangers of excessive screen time for kids

RELATED: Wear The Gown: Is it a headache? Migraine? Or something worse?

RELATED: The risks of drinking diet soda | Wear The Gown

"Miss Oliver is really a model patient. She's the perfect example of someone who, through lifestyle modifications, has been able to not only get her diabetes under control, but really throwing the diabetes into what we call remission," said Dr. Alberto Chavez, an endocrinologist with the Texas Diabetes Institute within the University Health System.

He added there has been some debate about what diabetes remission really means.

"The bottom line is that it is a reality that patients can get off of medications or many amounts of medications by making meaningful lifestyle changes," Chavez said.

That is exactly what Oliver did in cutting her medications from three to one.

"I take it faithfully and I know that I can't have two donuts in one sitting," she said. "I'm not depriving myself, but, by the same token, I just limit myself."

For more information about family health, call (210)358-3045. You can also find the rest of Wear The Gown stories, just go to WearTheGown.com.

See the original post:
Wear The Gown: Rolling back diabetes with diet and exercise - KENS5.com

Read More...

Type 2 diabetes symptoms: The change in your breathing pattern to watch out for – Express

Sunday, March 15th, 2020

Type 2 diabetes is a condition whereby the pancreas does not produce enough of the hormone insulin to regulate glucose in your blood, a type of sugar that you get from food and drink. With the pancreas out of action, blood sugar levels rise uncontrollably. This process can damage blood vessels, causing a number of life-threatening complications, such as heart disease.

This internal mechanism largely goes undetected in the beginning so people with type 2 diabetes often live with the condition for years before getting diagnosed.

Over time, however, high blood sugar levels can produce a number of noticeable signs.

One major warning sign to watch out for is shortness of breath, according to Mayo Clinic.

This symptom arises when blood sugar levels cause toxic acids to build up in your blood and urine, explains the health body.

READ MORE:How to live longer: Three reasons why paprika spice may increase your life expectancy

It is important to note that becoming short of breath can also indicate kidney failure, the most severe stage of kidney disease.

As Diabetes.co.uk, kidney disease is one of the more common complications of diabetes, affecting about 40 percent of people with diabetes.

Other symptoms associated with consistently high blood sugar levels include:

If you recognise any of the above symptoms associated with type 2 diabetes, you should see a GP immediately, says the NHS.

DON'T MISSCoronavirus symptoms: The one easily missed sign of the deadly virus you need to know[INSIGHT]Hair loss treatment: The essential oil proven to help hair growth with less scalp itching[TIPS]Coronavirus: Can Dettol kill the virus? Disinfectants you could use against the virus[TIPS]

As the health body points out, the earlier diabetes is diagnosed and treatment started, the better.

After receiving a diabetes diagnosis, a GP will usually recommend revising your lifestyle to lower your blood sugar levels.

One key aspect of blood sugar management is to improve your diet.

One tried-and-tested way to reduce your blood sugar levels is to restrict your intake of high-carb foods.

Foods with a high-carb content are broken down into blood sugar relatively quickly and therefore has a more pronounced effect on blood sugar levels than either fat or protein.

High-carb culprits include starchy foods such as rice, pasta and flour (therefore including pastry, bread and other dough based foods).

Following the Glycemic Index (GI) can help you differentiate between low and high-carb foods.

The Glycemic Index (GI) is a relative ranking of carbohydrate in foods according to how they affect blood glucose levels.

Carbohydrates with a low GI value (55 or less) are more slowly digested, absorbed and metabolised and cause a lower and slower rise in blood glucose and, usually, insulin levels.

Carbs that rank low on the GI index include:

Many whole grain breads and cereals (like barley, whole wheat bread, rye bread, and all-bran cereal)

The other key component of blood sugar management is regular exercise.

According to the NHS, you should aim for 2.5 hours of moderate-intensity exercise a week to keep blood sugar levels in check.

Read the rest here:
Type 2 diabetes symptoms: The change in your breathing pattern to watch out for - Express

Read More...

Coronavirus: how diabetes, asthma and other underlying health conditions affect how you cope – Telegraph.co.uk

Sunday, March 15th, 2020

As the number of UK cases of coronavirus continues to rise, what has become clear is how many of the patients to die from the virus have underlying health conditions that make them susceptible to catching it.

The death toll in Britain is up to 22. Of the latest deaths in the UK, eight were men aged over 80. All but one had known underlying health conditions.

Its a new infection, but from our experience with dealing with flu epidemics, we know that people with various conditions will fare worse, says Fan Chung, a professor of respiratory medicine at Imperial College. A paper has just published in the New England Journal of Medicine, that looked at the first 1,001 cases in Wuhan. The figures showed those with diabetes, high blood pressure, heart disease, COPD, cancer and renal disease, fared worse. And I suspect the people who very unfortunately died in the UK had one or any of those conditions."

A Chinese study hasfound people with heart disease, diabetes and cancer had a 79 per cent chance of being admitted to intensive care or dying from the virus, due to their weakened immune systems.

Here are the underlying health conditions that put you at higher risk of getting the coronavirus, anda reminder of how it might initially spread.

People with diabetes face a higher risk of complications if they get the coronavirus, due to the fact their fluctuating or elevated glucose levels leave them with lowered immunity. This also means they have less protection against getting the virus. Coronavirus or COVID-19 can cause more severe symptoms and complications in people with diabetes, says Dan Howarth from Diabetes UK. If you have diabetes and you have symptoms such as a cough, high temperature and feeling short of breath you need to monitor your blood sugar closely and call the NHS 111 phone service.

People with diabetes who dont experience symptoms and have recently travelled to any of the affected areas need to follow information on the NHS and theGOV.UKwebsites, adds Howarth. "These are updated regularly and are the most up-to-date source of information available.

Its believed around 40 per cent of hospitalised coronavirus patients have heart disease. Somebody with a heart condition is more likely to have a compromised immune system, so their immune response wont be as strong if exposed to a virus. COVID-19 also targets the lungs, which could cause problems for a diseased heart that has to work harder to get oxygenated blood around the body.

Asthma is a respiratory condition that leads to inflammation of the breathing tubes that transport air to and from the lungs.Coronavirus can cause respiratory problems for anyone, but for the 5.4million people in the UK with asthma, the risk is greater, says Jessica Kirby, Head of Health Advice at Asthma UK. Respiratory viruses like thiscan triggerasthma symptoms and couldlead to anasthma attack.

Kirby says if youre a sufferer, itsessential to takeyour preventer, daily as prescribed. This helps cut the risk of an asthma attack being triggered by any virus, including coronavirus, she says. Keeping a reliever inhaler to handis vital, soyoucan use it ifyou get asthmasymptoms.

Ifyourasthma symptomsgetworse, and you havent travelled to an at-risk area or been in contact with someone who has, make an appointment to see your GP as soon as you can. If you think you might have coronavirus, use the NHS 111 online coronavirus service."

COPD is the name for certain lung conditions that cause breathing difficulties, including emphysema, which is characterised by damage to the air sacs in the lungs,and chronic bronchitis, which is a long-term condition involving inflammation of the lungs airways. People with COPD are more likely to get coronavirus if exposed to the virus because they have damage to their epithelial lining, which makes it easier for viruses to enter the body.

Cancer patients are more susceptible due to their compromised immune system. Various cancer drugs and treatments, like chemotherapy, mean your immune system may be suppressed, says Prof Chung, and this would increase your chances of catching it. And if you do get it while you havecancer, you would probably fare worse than somebody with the virus who didnt have cancer.

Not a health condition as such, but many of the thousands of deaths so far have involved elderly people with underlying health conditions. The elderly are at greater risk, and government advice for the elderly to avoid crowded areas is sound advice, says Prof Chung. The figures we have so far seem to imply the risk increases above the age of 70. However its even worse for those over 80. The chances of getting it and faring worse increase two or three times above the age the 70, but even more so above 80.

In terms of children, who appear to be less prone to getting the coronavirus and, if they do, getting a more benign version of the illness, Prof Chung says that a young person with an underlying health condition isn't at a greater risk: A young person with asthma, or heart disease, wouldnt be predisposed to get the coronavirusor suffer from it, in the same way an adult with the condition would, he says. Maybe its their immune system, and how its different from older people, but in terms of their susceptibility of getting the coronavirus, health conditions in young people dont seem to increase their chances of catching it.

Link:
Coronavirus: how diabetes, asthma and other underlying health conditions affect how you cope - Telegraph.co.uk

Read More...

Evaluation of Factors Affecting the Severity of Diabetic Foot Ulcer in | DMSO – Dove Medical Press

Sunday, March 15th, 2020

Akram Ghobadi,1 Pegah Ahmadi Sarbarzeh,2 Milad Jalilian,2 Alireza Abdi,1 Sara Manouchehri3

1Nursing Department, Nursing and Midwifery School, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Nursing Department, Nursing and Midwifery School, Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Biostatistics Department, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence: Pegah Ahmadi SarbarzehNursing Department, Nursing and Midwifery School, Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, IranTel +98 930 1946547Email Ahmadi.pegah554@yahoo.com

Introduction: Diabetes mellitus is a metabolic disease characterized by high blood sugar (BS) levels and the change in the metabolism of lipids, carbohydrates, and insulin resistance, and is one of the main causes of disability and mortality worldwide. Among the different types of complications, which have many negative effects on personal and social life, diabetic foot ulcer (DFU) is very important. This study aims to investigate the factors affecting the severity of DFU among patients with diabetes.Methods: The study participants included 190 diabetic patients with a diagnosis of DFU. Data were collected using a two-part questionnaire for self-care awareness and functions in diabetic patients and Wagners scale. The questionnaire was answered in cooperation with patients and the Wagners score was estimated bya wound supervisor in the diabetes center.Results: There was 109 women (57.4%). Twenty-six patients had other diabetic complications as well as DFU. The average score of awareness in patients was 6.99 2.76 and the function was 62.22 9.92. The results found a direct relation between the age and the durationofillness with the score of the patients awareness (P=0.008, P=0.000). There was also a direct relation between the level of education with score of awareness and the score of function in self-care (P=0.000, P=0.000), but the statistical results did not find any relation between awareness and the function in self-care of patients with the severity of DFU (P> 0.05).Discussion: There was no relation between the self-care awareness and function with severity of DFU (P> 0.05) that can be due to the more relation between DFU severity with hygiene and physical factors after the disease and the effect of awareness and function would be only in the incidence of the DFU.Conclusion: Awareness and function of patients in self-care is less than average. Increasing awareness of patients and empowering them through appropriate training can be effective in preventing diabetic foot ulcers.

Keywords: diabetes, diabetic foot ulcer, diabetes complications

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:
Evaluation of Factors Affecting the Severity of Diabetic Foot Ulcer in | DMSO - Dove Medical Press

Read More...

What patients of diabetes, asthma need to do to stay safe from COVID-19 – ThePrint

Sunday, March 15th, 2020

Text Size:A- A+

New Delhi: Coronavirus, which is now officially a pandemic, is deadly, but not for everyone. Illness due to coronavirus, also called COVID-19, is generally mild, especially for children and young adults, according to the World Health Organization (WHO).

However, the early clinical profile of COVID-19 suggests severe manifestation in people suffering from diabetes, cardiovascular conditions and lung diseases like asthma and chronic pulmonary obstructive disorder (COPD).

These conditions are common among Indians for example, India ranks second in diabetes incidence, with an estimated 7.7 crore diabetics, according to the International Diabetes Foundations Diabetes Atlas.

Similarly, medical journal The Lancet found heart diseases and strokes to be one of the top reasons for deaths in India, where the number of cardiovascular disease patients reportedly increased to 5.45 crore in 2016 from 2.57 crore in 1990.

COPD was the second-strongest cause of death in India after heart disease in 2017, killing 9.58 lakh Indians that year, according to the University of Washingtons Global Burden of Disease study 2018.

Patients of these conditions need to exercise additional caution amid the spread of COVID-19, which, according to WHO, had killed over 3,500 people by 8 March.

Such patients are primarily advised to stock drugs for the long-term and take extra precautions, and ensure theyve received vaccines for influenza and pneumococcal infections, which include severe pneumonia.

Also Read:Forget coronavirus, homoeopathy cant cure anything. Its a placebo, at best

While data about COVID-19 in patients with diabetes is limited at present, the condition was present in 42.3 per cent of 26 fatalities in Wuhan, China, the epicentre of the pandemic, according to a Chinese study (which factored in data for December 2019-January 2020) published by the Switzerland-based, peer-reviewed Journal of Clinical Medicine in February.

Individuals with diabetes are at risk of infections, especially influenza and pneumonia. This risk can be reduced, though not completely eliminated, by good glycaemic control. All people with diabetes (above 2 years of age) are recommended pneumococcal and annual influenza vaccinations, said Dr Anoop Misra, chairman at Fortis, C-Doc, in a study co-authored by him.

The research, titled Diabetes & Metabolic Syndrome: Clinical Research & Reviews, was published in the latest edition (May-June) of ScienceDirect, a portal for peer-reviewed research.

Pneumococcal vaccines prevent infections caused by bacteria spread through person-to-person contact, which could lead to serious infections like pneumonia, blood infections, and bacterial meningitis.

Patients with diabetes generally contract severe infections due to respiratory viruses.

Diabetes was seen as an important risk factor for mortality in patients infected with Pandemic Influenza A 2009 (H1N1), Severe Acute Respiratory Syndrome (SARS) coronavirus and Middle East Respiratory Syndrome-related coronavirus (MERS-CoV), the aforementioned study said.

When people with diabetes develop a viral infection, it is often difficult to treat them due to fluctuations in their blood glucose levels and the presence of diabetes complications. Their immune system is compromised, Dr Mahesh DM, a consultant for endocrinology at Bengalurus Aster CMI Hospital.

Also, patients with Type-1 diabetes should measure blood glucose and urinary ketones frequently if fever occurs while blood glucose levels are high.

Frequent changes in dosage may be required to maintain normal sugar in the blood, Misra said.

Also Read: 10 reasons why you dont need to panic about coronavirus

While the specific impact of coronavirus infection on the cardiovascular system remains unclear, according to the American College of Cardiology, there have been reports of acute cardiac injury, arrhythmias, hypotension, tachycardia, and a high proportion of concomitant cardiovascular disease in infected individuals, particularly those who require more intensive care.

Arrhythmia means irregular heartbeats while hypotension refers to abnormally low blood pressure and tachycardia to rapid heartbeats.

Patients who have undergone angioplasty or have a stent inside their hearts are believed to be more vulnerable to severe COVID-19 infection. The virus can cause tears in a patients blood vessels and then lead to secondary infections.

Influenza virus is already known as a propellant for heart attacks. The patients who are on blood-thinning medications, their chances of bleeding from lungs become high in case of coughing, such as in the case of coronavirus infection, said Yugal Kishore Mishra, head of cardiac sciences at Manipal Hospital in Delhi.

Based on an advisory from the US Centres for Disease Control and Prevention (CDC), doctors recommend that cardiac patients should take flu and bacterial pneumonia vaccinations.

When the body is fighting a major pathogen like coronavirus, it becomes vulnerable to other viruses and bacterial infections. The vaccine for flu and pneumonia will reduce the chances of death in case of coronavirus infections, said Dr K.K. Aggarwal, a cardiologist and former president of the Indian Medical Association (IMA).

Doctors also recommend immunity boosters along with a nutritious diet. I prescribe regular doses of Vitamin C and B-complex along with vaccination to the susceptible category, Mishra added.

Apart from stocking their routine medicines and inhalers, patients, experts advise, should consult doctors about new dosage requirements, if any.

With the summer coming, several patients re-adjust and reduce the dosage. In the winter, they generally need higher doses. This time, I recommend all patients to check with their doctors about the required dosage, said Dr Navneet Sood, pulmonology consultant at Dharamshila Narayana Superspeciality Hospital in Delhi.

We advise flu vaccines and pneumococcal vaccines apart from wearing N-95 masks, even if you are feeling healthy.

Also Read:Funny videos, TikTok dances, serious info how social media has responded to coronavirus

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Read the original:
What patients of diabetes, asthma need to do to stay safe from COVID-19 - ThePrint

Read More...

Chester woman won’t let diabetes get in the way of her first London Marathon – Cheshire Live

Sunday, March 15th, 2020

A woman from Chester is preparing to run her first marathon three years after being diagnosed with type 1 diabetes.

Kirsten Gooderham, 26, of Huntington, will take on the Virgin Money London Marathon on Sunday, April 26.

She is well on course to raise more than 2,000 in sponsorship for Diabetes UK, a charity which she says has transformed her life since her diagnosis in April 2017.

Type 1 diabetes causes the level of glucose in the blood to become too high. It happens when the body cant produce enough of a hormone called insulin, which controls blood glucose.

Type 1 diabetes is treated by daily insulin doses taken either by injections or via an insulin pump.

People with type 1 diabetes need to check their blood glucose levels are not too low or too high by using a glucose testing device several times a day.

Diabetes UKs Fight for Flash campaign empowered Kirsten to push for a flash glucose monitor. The device sits under the skin and measures the amount of sugar in the fluid under the skin, called interstitial fluid.

It has made it much easier for the former Chester Queens School pupil to manage her diabetes and run regularly in her free time.

Kirsten said: Flash means I no longer have to prick my fingers eight times a day in order to know my glucose readings. I can scan my arm and know within seconds what my levels are, 24/7.

Its changed my life completely and I have Diabetes UK to thank for that.

As well as reducing the need for as many finger pricks, the technology makes it easier to see when sugar levels are starting to rise or drop, meaning people can take action earlier.

Kirsten finds the monitor particularly useful when she is training and also uses an insulin pump, which she says is a massive help.

She added: Running is hard enough as it is, in terms of what to eat before a run, what to eat after. Now I have diabetes, its a constant battle of making sure Ive got enough carbs on board, and not having too many.

The main thing I found is you need to get into a routine to get out there and practice. Sometimes it goes wrong and you just have to move on and learn from it.

Sometimes it goes right, and its very rewarding when that happens.

Kirsten, who works as a production planner at a Deeside car engine factory, ran her first half-marathon while she was at university.

She had to pull out of the Chester Half Marathon in 2017 as it was due to take place soon after she was diagnosed with diabetes.

However, she managed to run it the following year and this year she will be stepping up to the full 26.2 miles in London for the first time.

The big run takes place three years and two days on from Kirstens diagnosis.

Clare Howarth, head of the North of England at Diabetes UK, said: Our much-needed work wouldnt be possible without the determination and generosity of our incredible fundraisers.

We are extremely grateful to Kirsten for her hard work running a marathon is no mean feat! The money raised will help fund ground-breaking research, care services and campaigns that can change the lives of those living with diabetes.

To sponsor Kirsten, please visit: https://justgiving.com/fundraising/Kirsten-Gooderham.

More here:
Chester woman won't let diabetes get in the way of her first London Marathon - Cheshire Live

Read More...

Standardised self-management kits for children with type 1 diabetes: pragmatic randomised trial of effectiveness and cost-effectiveness. – DocWire…

Sunday, March 15th, 2020

This article was originally published here

Standardised self-management kits for children with type 1 diabetes: pragmatic randomised trial of effectiveness and cost-effectiveness.

BMJ Open. 2020 Mar 12;10(3):e032163

Authors: Noyes J, Allen D, Carter C, Edwards D, Edwards RT, Russell D, Russell IT, Spencer LH, Sylvestre Y, Whitaker R, Yeo ST, Gregory JW

AbstractOBJECTIVE: To estimate the effectiveness of standardised self-management kits for children with type 1 diabetes.DESIGN: Pragmatic trial with randomisation ratio of two intervention: one control. Qualitative process evaluation.SETTING: 11 diabetes clinics in England and Wales.PARTICIPANTS: Between February 2010 and August 2011, we validly randomised 308 children aged 6-18 years; 201 received the intervention.INTERVENTION: We designed kits to empower children to achieve glycaemic control, notably by recording blood glucose and titrating insulin. The comparator was usual treatment. OUTCOME MEASURES AT 3 AND 6 MONTHS: Primary: Diabetes Pediatric Quality of Life Inventory (PedsQL). Secondary: HbA1c; General PedsQL; EQ-5D; healthcare resource use.RESULTS: Of the five Diabetes PedsQL dimensions, Worry showed adjusted scores significantly favouring self-management kits at 3months (mean child-reported difference =+5.87; Standard error[SE]=2.19; 95% confidence interval [CI]) from +1.57to +10.18; p=0.008); but Treatment Adherence significantly favoured controls at 6months (mean child-reported difference=-4.68; SE=1.74; 95%CI from -8.10 to -1.25; p=0.008). Intervention children reported significantly worse changes between 3 and 6months on four of the five Diabetes PedsQL dimensions and on the total score (mean difference=-3.20; SE=1.33; 95%CI from -5.73 to -0.67; p=0.020). There was no evidence of change in HbA1c; only 18% of participants in each group achieved recommended levels at 6 months. No serious adverse reactions attributable to the intervention or its absence were reported.Use of kits was poor. Few children or parents associated blood glucose readings with better glycaemic control. The kits, costing 185, alienated many children and parents.CONCLUSIONS: Standardised kits showed no evidence of benefit, inhibited diabetes self-management and increased worry. Future research should study relationships between children and professionals, and seek new methods of helping children and parents to manage diabetes.TRIAL REGISTRATION NUMBER: ISRCTN17551624.

PMID: 32169923 [PubMed as supplied by publisher]

See the original post:
Standardised self-management kits for children with type 1 diabetes: pragmatic randomised trial of effectiveness and cost-effectiveness. - DocWire...

Read More...

Why the UKs NHS leads the world in managing diabetes – Financial Times

Sunday, March 15th, 2020

While the UKs taxpayer-funded National Health Service suffers its share of criticism, its approach to the management and prevention of diabetes is widely recognised as world-leading.

Single-payer systems such as the NHS tend to perform well when it comes to the management of chronic diseases. In contrast to insurance-based provision, where people may move between providers every few years, compromising continuity of care, the NHS generally cares for its patients without interruption and free of charge for a lifetime.

This, in turn, creates the conditions in which a chronic disease such as diabetes can be effectively monitored and managed.

Jonathan Valabhji, a consultant diabetologist who combines his work as a doctor at Londons Imperial College Healthcare NHS Trust with his role as national clinical director for diabetes and obesity in NHS England, says the concept of free healthcare for all at the point of need is particularly well suited to chronic diseases, and in some respects diabetes is the classic chronic disease. Once you develop it, most people will have it for the rest of their lives.

The numbers underline the scale of the challenge facing the NHS. Statistics issued last month by NHS England show that almost 2m patients registered with a GP have non-diabetic hyperglycaemia, a condition which puts them at high risk of developing type-2 diabetes, the form of the disease linked to lifestyle.

Dr Valabhji says estimates suggest that about 10 per cent of the entire annual NHS budget is now being spent on people with diabetes. So it has a significant impact on the sustainability of the health system moving forward.

As a clinician, he is now diagnosing people at earlier and earlier ages. Since many of the complications that accompany diabetes, such as eye, kidney or foot disease, increase in prevalence the longer someone has the condition, this in turn has a big potential impact within the health service in the decades to come, he points out.

FT correspondents unearth the ways cities are helping their citizens live healthier lives, from doctors who prescribe exercise rather than pills, to a car-free economy that is booming. Listen to the series

To tackle this seemingly unrelenting tide of current and prospective cases, the NHS has worked to incentivise doctors to focus on treating the condition.

Since 2003 about 15 per cent of GP income has been related to delivering specific aspects of care. Of that, a significant proportion is focused on diabetes care, Dr Valabhji says, which I think has had an important impact on the quality of care across the country.

At the same time the NHS established a national diabetes audit, to track the effectiveness of care of patients, not only with type-2 diabetes, but also with type-1, an autoimmune disease that is not susceptible to lifestyle changes.

Perhaps its most far-reaching initiative is a national diabetes prevention programme that is the biggest of its type in the world and to which more than half a million people have been referred since it was established in 2014. By 2023-24 up to 200,000 people a year are expected to participate.

One of the innovative approaches that the NHS has adopted reflects recent evidence that limiting peoples dietary intake to just over 800 calories a day for three months can cause significant weight loss. Strikingly, in the case of people recently diagnosed with type-2 diabetes, the condition can actually be put into remission.

The NHS has also been at the forefront of exploring digital interventions to help overweight or obese people lose weight in order to prevent type-2 diabetes or to lessen the impact in those already diagnosed with the condition.

Among those whose innovations have been taken up the by NHS are Chris Edson and Mike Gibbs, two young engineers who set up a company called Second Nature. It uses a blend of technology such as smart weighing scales linked to an online app and professional and peer support to help people make the lifestyle changes that can ward off diabetes.

Second Nature has recently been accepted as a national provider for the diabetes prevention programme. Crediting the NHSs forward-thinking approach, Mr Edson says: There arent many health organisations in the world that have put their neck out and said, yes, we believe that digital has the outcomes for diabetes prevention and management and were going to commission it nationally.

His companys clients, he says, are people in the risk zone for diabetes. Our programme is to get them out of the risk zone. Separately it also offers a programme aimed at putting people who already have diabetes into remission.

We help them make such drastic lifestyle changes that they actually [no longer meet] the diagnostic criteria for type-2 diabetes and they come off all of their medication, he says. Data it has recently published in a professional journal show that it has achieved this feat in 40 per cent of cases, he adds.

Within five years, wed like to eradicate type-2 diabetes within the UK

About 5,000 NHS patients have already gone through the programme, for which people can also choose to pay themselves without a doctors referral.

Mr Edson has a striking ambition for Second Nature, which recently raised $10m in a venture capital funding round: Within five years, wed like to eradicate type-2 diabetes within the UK. Combined with other initiatives that the NHS is doing, I think its a realistic goal.

Meanwhile Dr Valabhji is awaiting data on the impact of the national diabetes prevention programme nationally, confident that it will show a reduction in the rate of growth in diabetes cases in England.

Results so far are extremely encouraging and I think it will be around 2021 that were able to show an impact on the trajectory of type-2 diabetes incidence, he says.

See the article here:
Why the UKs NHS leads the world in managing diabetes - Financial Times

Read More...

Cyndi Williams on tech for diabetes and ‘showing love’ at work – Siliconrepublic.com

Sunday, March 15th, 2020

Cyndi Williams, CEO of diabetes-focused tech start-up Quin, discusses career paths, company culture and her exceptional co-founder.

Cyndi Williams is the co-founder and CEO of Quin, an app designed to help people with diabetes keep track of their insulin.

The app works with data logged into a mobile device, along with continuous glucose monitoring (CGM) devices, to enable people with diabetes to recognise patterns and rely less on trial and error when it comes to insulin administration.

The question that were focused on at Quin is how much insulin a person should take and when, Williams told Siliconrepublic.com. Thats a question that millions of people with insulin-treated diabetes need to answer several times a day, and no one knows the exact answer.

Williams explained that most people with diabetes have to figure out the answer to that question every day, making important healthcare decisions using their own intuition and knowledge of experience.

The goal is to formalise the knowledge of Quin users, with the aim of contributing that data to diabetes research in order to advance personalised medicine for insulin-treated diabetes.

From left: Vanessa Bolosier and Isabella Degen. Image: Quin

We made a mobile app that takes data from existing CGM devices for diabetes, which is a sensor often worn on the arm to measure blood glucose. People also use insulin pens or syringes to inject insulin, and all of our users use an iPhone, Williams said.

We take data off of those devices, we take their activity data from their phone, and we use it to observe and learn how each individual is doing their trial and error on a day-to-day basis as they are going about their lives, and give them advice in the moment they need it, based on their past experience.

One example she gave was ordering a coffee. You may have drank hundreds of lattes in your life and dosed anywhere from zero to five units for lattes. How much should you take for this latte?

Quin would look at how long you slept for last night, how active you have been in the past 24 hours, what insulin you have onboard already, where you are in your menstrual cycle and how you feel in terms of stress.

We look at all of those factors and things that are affecting you, and we go into your past and find the latte decision that is most relevant for you and most closely matches your current situation, then give that to you as the basis for making your decision.

London-based Quin was founded in 2014, but how did Williams end up in the world of diabetes tech?

It was a couple of things, but mainly my interest in Isabella Degen, my co-founder. My background is in chemical engineering and software engineering, but Ive been on the business side of engineering for the last 15 years.

Prior to setting up Quin, Williams worked at Sun Microsystems before becoming a managing director at software and services business ThoughtWorks. This is where she met Degen, also an engineer, whose own diabetes had inspired a potential business idea.

At the time I didnt know anything about diabetes, Williams said. I didnt even know she had diabetes! I just knew how exceptional she was and she was looking for someone to help her set up a business.

Williams added that she was excited to solve a human problem with technology, and that the whole idea tickled the nerve of the engineer within her. Its also a dream to be able to do something that could actually make a material difference to peoples lives.

From left: Cyndi Williams and Isabella Degen. Image: Quin

With an official launch planned for later this year, Quin has been developed behind closed doors for the last two years as part of a research programme with around 100 people who have been providing feedback, ideas and thoughts on the design.

We are a regulated medical device company, Williams said. Every release of our app is a regulated medical device that is released and pushed out to our market. We want to do a human-centred co-creation of a medical device, while also ensuring that what we are doing is safe, will not hurt anyone and will improve the lives of users.

As part of that, we do regular self-reported results from our users and look at three categories of metrics, which are quality of life improvements, medical benefits and behavioural changes that people make.

We have had 76pc of our users reporting that they feel more confident, relaxed and that life with diabetes is easier, from the quality of life point of view. Thats something were very proud of. Its critical as a software product maker that youve got to make a material difference to peoples quality of life.

Aside from tech and engineering, one area of business that Williams is particularly interested in is workplace culture. She spent much of her time in leadership roles at ThoughtWorks coming up with the values, living the values and leading by the values.

What were doing now, our mission is very human-centred and is about making life better for potentially millions of people, she explained. Its really about the values that you put underneath that. For us, our values are quite simple: be excellent, find truth and show love.

The Quin team. Image: Quin

For us, excellence is your interest in collaborating across the areas of the discipline and your ability to draw people in and take people with you on that journey, Williams added.

Finding truth is about the fact that we know so little about diabetes, as well as being willing to throw away our truths when we have to and the problem-solving nature of who we are as people.

The third value is to show love, which is about the space that we live in. Because diabetes is so poorly understood, theres a lot of hurt that happens to people who are living with diabetes. It starts with love for the people we are creating for and working with, but it extends to love for your colleagues.

Although a launch is upcoming, Williams said that the mission of Quin could take 10 years or more. This is hard work certainly the hardest work of my life and the lives of many people who work here. We have to have an unconditional positive regard for each other and really be willing to walk in each others shoes.

To ensure that Quin hires the right people, Williams said that she selects interviewees based on their technical skills as well as their affinity to those values. She added that she asks some pretty pointed questions during the interview process to ensure that new hires share those values.

Its about living those values when were inside and what we do every day and how we behave. It matters. Isabella and I have only ever been in value-based organisations, so if you grow up with it, its sort of second nature.

Want stories like this and more direct to your inbox? Sign up forTech Trends, Silicon Republics weekly digest of need-to-know tech news.

The rest is here:
Cyndi Williams on tech for diabetes and 'showing love' at work - Siliconrepublic.com

Read More...

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard…

Sunday, March 15th, 2020

This article was originally published here

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol.

BMJ Open. 2020 Mar 12;10(3):e033500

Authors: Boughton C, Allen JM, Tauschmann M, Hartnell S, Wilinska ME, Musolino G, Acerini CL, Dunger PD, Campbell F, Ghatak A, Randell T, Besser R, Trevelyan N, Elleri D, Northam E, Hood K, Scott E, Lawton J, Roze S, Sibayan J, Kollman C, Cohen N, Todd J, Hovorka R, CLOuD Consortium

AbstractINTRODUCTION: Management of newly diagnosed type 1 diabetes (T1D) in children and adolescents is challenging for patients, families and healthcare professionals. The objective of this study is to determine whether continued intensive metabolic control using hybrid closed-loop (CL) insulin delivery following diagnosis of T1D can preserve C-peptide secretion, a marker of residual beta-cell function, compared with standard multiple daily injections (MDI) therapy.METHODS AND ANALYSIS: The study adopts an open-label, multicentre, randomised, parallel design, and aims to randomise 96 participants aged 10-16.9 years, recruited within 21 days of diagnosis with T1D. Following a baseline mixed meal tolerance test (MMTT), participants will be randomised to receive 24 months treatment with conventional MDI therapy or with CL insulin delivery. A further 24-month optional extension phase will be offered to all participants to continue with the allocated treatment. The primary outcome is the between group difference in area under the stimulated C-peptide curve (AUC) of the MMTT at 12 months post diagnosis. Analyses will be conducted on an intention-to-treat basis. Key secondary outcomes are between group differences in time spent in target glucose range (3.9-10 mmol/L), glycated haemoglobin (HbA1c) and time spent in hypoglycaemia (<3.9 mmol/L) at 12 months. Secondary efficacy outcomes include between group differences in stimulated C-peptide AUC at 24 months, time spent in target glucose range, glucose variability, hypoglycaemia and hyperglycaemia as recorded by periodically applied masked continuous glucose monitoring devices, total, basal and bolus insulin dose, and change in body weight. Cognitive, emotional and behavioural characteristics of participants and parents will be evaluated, and a cost-utility analysis performed to support adoption of CL as a standard treatment modality following diagnosis of T1D.ETHICS AND DISSEMINATION: Ethics approval has been obtained from Cambridge East Research Ethics Committee. The results will be disseminated by peer-reviewed publications and conference presentations.TRIAL REGISTRATION NUMBER: NCT02871089; Pre-results.

PMID: 32169925 [PubMed as supplied by publisher]

View post:
Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard...

Read More...

Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS,…

Saturday, March 14th, 2020

With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development

MINNEAPOLIS, March 12, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (POAI) (POAI or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announces it will launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS) through an operating agreement with Soluble Therapeutics. POAI has also signed a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its assets and its HSCTM Technology.

Global health experts are predicting an ever-increasing number of viral outbreaks like COVID-19, POAI is taking proactive measures to be part of the solution by applying artificial intelligence to aid in the development of new drugs and vaccines. Utilizing Soluble Therapeutics HSCTM technology and its six machines, Soluble's computer system expects to be able to run over 12,000 computer simulations per machine to help generate new diagnostics, vaccines and therapeutics. Solubles HSCTM technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pandemics and battle cancers.

The market for biologicals that includes vaccines, proteins and antibodies used in disease treatment is projected to reach $479.7 billion by 2024 at a compound annual growth rate (CAGR) of 10.9%.* The capital the US Congress has allocated to fight COVID-19 is $8.0 billion dollars.

Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics technology directly addresses this bottleneck.Combining the HSCTM technology with POAIs predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates. The HSCTM technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. The HSCTM technology only requires milligrams where a traditional formulation effort can require up to a gram of material.

HSC Technology is a self-contained, automated, chromatographic system that conducts high throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.

The HSC Instrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients and vaccine manufacturers, this means faster development times and quicker progression of molecules into the clinic. The COVID-19 vaccine development efforts by industry and government can benefit enormously using the Soluble HSCTM technology with POAIs predictive modeling platform.

Soluble hassix customized machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion. Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments, said Carl Schwartz, CEO of Predictive Oncology.

The combination of Soluble Therapeutics technology with Predictive Oncologys AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development, said Dr. Larry DeLucas, co-inventor of the HSC technology.

Under the operating agreement, the Company and existing Soluble managers will operate the Soluble Therapeutics business pending the acquisition. The Company's acquisition of Soluble Therapeutics is subject to the completion of a definitive agreement and customary closing conditions and is expected to close in the second quarter of 2020.

Story continues

*Global Biologics Market to touch US$479 Billion Dollars by 2024. Transparency Market Research. Feb 2018. Web.

About Predictive Oncology Inc.

Predictive Oncology (POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients specific needs. Predictive Oncologys TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis Oncology Capture Technology Platforms which isolate and help categorize an individual patients heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncologys Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.predictive-oncology.com.

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Companys business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) the risk that the acquisition ofSoluble Therapeuticswill not be completed, or, if completed, that the Soluble Therapeutics technology does not provide anticipated benefits to the Company or involves higher costs than anticipated or other negative consequences, (ii) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Companys and Helomics existing businesses, distraction of management and diversion of resources; and the market price of the Companys common stock may decline as a result of the merger; (iii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iv) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictives ability to implement its long range business plan for various applications of its technology; Predictives ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictives technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Companys reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictives financial position. See Predictives most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Contact:Bob Myers651-389-4800bmyers@skylinemedical.com

Source: Predictive Oncology Inc.

See more here:
Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS,...

Read More...

Running Your Pharma Company Out Of A Starbucks: Drug Discovery Moves To The Cloud – Forbes

Saturday, March 14th, 2020

Fifteen years and $2.5 billion dollars is too much to get a drug to market that many cannot even ... [+] afford. Solution: put big pharma in the cloud, and make drug discovery possible from a coffee shop.

Small biotech start-ups accounted for 63% of all new prescription drug approvals in the last five years. And the way that many big drug companies are establishing their own venture capital funds to invest in small, innovative start-ups, its easy to argue that big pharma isnt doing much innovation these days.

Whats going on here?

You can literally sit at a Starbucks, design a compound, have the robots assemble that compound and go through the purification and analysis steps to validate what youve made, Mark Fischer-Colbrie tells me. Hes the President and CEO of Strateos, and his company is taking all the processes, instruments, and robotics youd find in a big pharmaceutical R&D facility and making them accessible to anybody with a laptop and a good idea.

This is the lab of the future, where automated drug discovery can be done from the comfort of a coffee shop. The capital investments associated with traditional pharmaceutical research and development are gone. And perhaps most importantly for Fischer-Colbrie, this is the foundation biology needs to become industrialized.

Combining automation in biology and chemical synthesis while leveraging big data and machine learning, Strateos Robotic Cloud Lab is a platform for biological discovery at unprecedented speed, reproducibility, and cost-effectiveness.

Combining forces with Eli Lilly and Company, Strateos powers a robotic cloud laboratory that can compress a three-and-a-half year drug discovery cycle into 12 months. Open to a wide range of usersfrom big pharma through to synthetic biology and academiathe company has triggered a high-throughput revolution in life science.

If you look broadly across life sciences, I would estimate more than 90% of the workflows are manual, with uncertain data capture, say Fischer-Colbrie, reflecting on the status quo of most lab research today. In order to advance discovery, all of this needs to get industrialized, which means automation, it means repeatability.

A reproducible platform for better drug discovery

Therein lies a huge benefit for companies and consumers: the drastically improved reproducibility of Strateos automated workflows. Science is in the grips of a replication crisis. A Nature report not too long ago showed that 70% of academics had tried and failed to reproduce anothers experiment. One study of cancer research showed that the rate of converting preclinical cancer research to successful treatments was as low as 11%. The rate for drugs, in general, has previously been reported at somewhere around 25%.

The result of this? A long, wasteful, and expensive drug discovery process, with small numbers of expensive therapies available to patients.

To be in an environment that takes 15 years and $2.5 billion dollars to get a drug to market that no-one can pay for is a broken model that needs to be rectified, Fischer-Colbrie laments. And though there are various reasons for the lack of translation of science findings, reproducibility of the method is a huge component. Strateos platform provides the robust, automated design-make-test-analyze technology that can turn things around.

Fischer-Colbrie tells me that after youve designed a drug from the corner coffee shop, You then have the whole biological testing piece looking at dose-response curves, and all the other criteria youd need to make first level assessments of whether that compound might make a good therapy or not.

Fast-track cancer therapies

Strateos is a merger of Transcriptic and 3Scan. The former has a focus on high-throughput biology, and the latter focuses on making tissue biology and histopathology into data science. Combining these competencies within Strateos means the company well-suited to applying its technology platform for cancer.

Instead of spending the painstaking hours to prepare samples manually, you can take samples from a patient, slice them into micron-thin slices and deposit them automatically on a tape. You can then look at your 3D image and run a range of different analysesit might be some transcriptomics on slice 18, or immunohistochemistry on slice 19.

Tissue handling is a huge bottleneck currently, but this is a new way of getting data in a totally different manner, Fischer-Colbrie explains. The 3scan offering has the benefit of being able to generate new datasets that in turn you can then use the San Diego lab to come up with compounds that might work against what youve found in those tissue samples.

Focus on the concept

Strateos has created an entire life sciences discovery foundry, and one which is providing the necessary step to turn laboratories into data generation engines - launching biology as an information science.

Fischer-Colbrie enthusiastically stresses that it really allows scientists to focus on concept. Theyre not thinking about how to maintain equipment, or which company they have to negotiate complicated contracts with. Scientists can focus on their hypotheses and experiments and not the infrastructure or day to day worries in the lab.

Its a game-changer, and one that improves the quality of hypothesis-driven research in general.

You can watch experiments happen online, get the data rapidly, and feed into machine learning models that provide whole new hypotheses overall, notes Fischer-Colbrie, along with another crucial point. These data, importantly, also include metadata such as environmental conditions and the status of the equipment. So, if you get an anomalous result, you can go back and understand what was going on at the time.

A range of industries set to reap the rewards

In the short term, Strateos platform will be open to a range of potential uses across the life sciences, from big pharma through to personalized medicine and even work in large molecules such as antibodies.

In synthetic biology, in particular, Fischer-Colbrie is excited about the platforms ability to rapidly accelerate experiments and to optimize conditions for gene editing. Its stunning in the context of the ability here to turn ideas into data. We believe in some cases this can happen in as little as 48 hours. This will have a significant improvement in the cycle time of experimentation and design.

The world is gradually shifting from standalone instruments to automated work cells, and now we really have to think about data generation and how to analyze that data. He concludes. Were excited about how this will have an impact across the board.

Follow me on twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology and space settlement.

Thank you to Peter Bickerton for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write aboutincluding Strateosare sponsors of the SynBioBeta conference and weekly digest heres the full list of SynBioBeta sponsors.

Excerpt from:
Running Your Pharma Company Out Of A Starbucks: Drug Discovery Moves To The Cloud - Forbes

Read More...

3D printing ink may solve the "toothpaste problem" – Futurity: Research News

Saturday, March 14th, 2020

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A new kind of ink for 3D printing liquifies when pressed through the nozzle of a 3D printer, but then quickly returns to its original shape, researchers report.

The invention paves the way for personalized biomaterial implants, according to new research.

In the same way that medicine has seen a trend towards precision medicinewhere doctors tailor treatment to the genetic make-up of the patientin recent years, materials scientists have increasingly turned their attention to precision biomaterials. As things stand, however, personalized implants remain a long way off.

But at the moment, were making great progress toward this goaland learning a lot in the process, says Mark Tibbitt, a professor of macromolecular engineering in the mechanical and process engineering department at ETH Zurich.

Previously, the fact that researchers had to develop new [A1] inks for the 3D printer for each application held back researchers working in the field of precision biomaterials.

If someone wanted to replicate part of an eye, for instance, they werent able to draw on the work of people who design auricular prostheses, Tibbitt explains. But now, he and his team have invented a universal carrier ink that dramatically simplifies the development of new applications, the researchers write.

Essentially, 3D printing calls for a solution to a conundrum casually referred to as the toothpaste problem. On one hand, toothpaste should not be too viscous as that would make it difficult to squeeze through the narrow opening of the tube; on the other, it cant be too fluid because it would then immediately drip off the toothbrush.

Similarly, in 3D printing, the carrier ink needs to be able to liquify to flow through the printing nozzle, and then solidify so that the printed structure does not immediately lose its shape.

This is where the universal carrier ink that Tibbitts team has developed can help. It consists of cellulose fibers dissolved in water combined with biodegradable polymeric nanoparticles. When no external pressure is exerted, the fibers attach themselves to the particles. This creates a transient network that can be disrupted when subjected to the high shear forces in the printer nozzlebut that quickly reforms after passing through the narrow opening.

In further experiments, Tibbitt and his team added different polymers (such as hyaluronic acid, gelatine, collagen, or fibrinogen) to their new carrier ink. These secondary polymers did not change the inks flow behavior through the head of the printer nozzle, but enabled the researchers to solidify the transient network to form the printed structure in a second, subsequent step.

Tibbitts team also tested how living cells behave in the carrier inkand found that the same number of cells survive in the ink as they do outside. Based on the fact that researchers can introduce hydrophobic substances into the nanoparticlesand add hydrophilic substances to the aqueous phase with the cellulose fibersthey demonstrated that their ink is also suitable for the development of novel drug delivery systems.

The research appears in the journal Small.

Source: ETH Zurich

Read the rest here:
3D printing ink may solve the "toothpaste problem" - Futurity: Research News

Read More...

Page 23«..1020..22232425..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick